GlassScriptPhysician profile
Christina Vasquez
NPI 1649933516
$3,196.27
in general payments reported to CMS, 2019-2025
21 companies · $1,519 in 2025
The $1,519 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $28.35 · 2023: $373 · 2024: $1,276 · 2025: $1,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,155 · Education: $13.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,154.85 |
| Education | $13.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $638.86 | 2023-2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $461.04 | 2023-2025 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.36 | 2023-2025 | Caplyta |
| Abbvie INC. | $318.82 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $227.73 | 2024-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $214.93 | 2023-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $207.10 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $187.91 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $127.79 | 2025 | Qelbree |
| Lundbeck LLC | $114.50 | 2023-2024 | Rexulti |
| Tris Pharma INC | $95.72 | 2023-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $67.81 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $50.06 | 2025 | Jornay Pm |
| Hologic Sales and Service, LLC | $28.35 | 2022 | |
| Corium, LLC | $25.78 | 2024 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $23.12 | 2025 | Cobenfy |
| Bausch Health US, LLC | $19.26 | 2025 | Aplenzin |
| Neuronetics, INC. | $16.41 | 2023 | Neurostar Tms Therapy System |
| Gilead Sciences, INC. | $15.61 | 2024 | Veklury |
| Neurocrine Biosciences, INC. | $15.53 | 2025 | |
| Noven Therapeutics, LLC | $13.58 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Vasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.